Navigation Links
Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
Date:11/27/2012

RICHMOND, Calif., Nov. 27, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), announced today that it will host a live webcast of its upcoming Analyst and Investor Briefing which will be held in New York City at 5:00 pm ET on Thursday, December 6, 2012.  During the briefing, members of Sangamo's management team will provide an update on the company's technology platform advancements and pipeline of ZFP Therapeutics® as well as near- and mid-term operating goals.

The presentations may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. A replay of the presentations will be archived on the Sangamo website and will be available approximately two hours after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as sickle cell anemia and beta-thalassemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
3. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
4. Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
5. 3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
6. Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinsons Blood Test Joint Venture
7. IntelliCell BioSciences Announces FDA Registration for its Cell Processing Facility
8. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
9. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
10. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
11. Advantages of Pressure BioSciences PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... CUPERTINO, Calif. , Feb. 24, 2017  In ... fourth quarter 2016 financial results press release, you are ... be broadcast live over the internet on Tuesday, March ... Pacific Time). A live audio webcast of ... at www.durect.com and clicking "Investor Relations."  If ...
(Date:2/24/2017)... Report analyzes the worldwide markets for Endodontic Supplies ... the US, Canada , Japan ... , Latin America , and Rest ... period 2015 through 2022. Also, a six-year historic analysis is ... from primary and secondary research. Company profiles are primarily based ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017  This ... US$ Thousand by the following Products: ... analyzed in the report include Pharmaceuticals, and Agrochemicals. The ... Japan , Europe , ... provided for the period 2015 through 2022. Also, a ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will ... the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace ... analytics to improve Medicaid population health management. , ODH will also have an exhibit ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have ... from Pixel Film Studios. With ProSharpen Color users have total control over sharpening amount, ... their color range. With color spectrum tools users can visually see the color range ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release of ... in Cannes (France), XO Private has initiated a second print-run of its lavish luxury ... a metre across when open, weighs in at more than six kilos, retails at ...
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of ... critically important that we all are aware of our options and are empowered ... to announce the launch of its newest edition of "Vision and Hearing" in ...
Breaking Medicine News(10 mins):